Role of dietary histidine in the prevention of obesity and metabolic syndrome

James J DiNicolantonio,1 Mark F McCarty,2 James H OKeefe

HISTIDINE SUPPLEMENTATION AMELIORATES METABOLIC SYNDROME

A recent Chinese supplementation study, in which obese middle-aged women diagnosed with metabolic syndrome received 12 weeks of supplemental histidine (2g, twice daily) or matching placebo, achieved remarkable findings.1 Histidine sensitivity improved significantly in the histidine-supplemented subjects, and this may have been partially attributable to loss of body fat. Body mass index (BMI), waist circumference and body fat declined in the histidine-supplemented group relative to the placebo group; the average fat loss in the histidine group was a robust 2.71 kg. Markers of systemic inflammation such as serum tumour necrosis factor-alpha (TNF-α) and interleukin (IL)-6, non-esterified fatty acids and oxidative stress also decreased in the histidine group. Subsequently, precisely parallel findings were reported in female rats rendered obese with a high-fat diet.2

BRAIN HISTAMINE INFLUENCES APPETITE AND METABOLIC RATE

These intriguing findings were not altogether unexpected, as earlier rodent studies had shown that supplemental histidine tends to inhibit food intake, via an impact on the hypothalamus that is mediated by the neurotransmitter histamine.3–6 Acting via H1 receptors in the ventromedial and paraventricular hypothalamic nuclei, histamine suppresses feeding behaviour, promotes adipocyte lipolysis via sympathetic activation and raises metabolic rate.3–7 These effects are analogous to those of leptin on the brain, and indeed histamine has been shown to be a key mediator of leptin signalling in the hypothalamus.4–9 Leptin triggers histamine release in the hypothalamus, and histamine in turn prevents the downregulation of leptin receptors which mediates leptin resistance. Crucially, whether administered intraperitoneally or intraventricularly, histidine dose dependently increases hypothalamic levels of histamine as well as hypothalamic activity of histidine decarboxylase, the enzyme which converts histidine to histamine.10 Such administration also inhibits food consumption—an effect that is blocked in animals pretreated with an irreversible inhibitor of histidine decarboxylase.

Neuronal histamine release in the hypothalamus is subject to feedback regulation by presynaptic H3 receptors. In rodent studies, antagonists and inverse agonists for these receptors have been shown to markedly amplify hypothalamic histamine levels, suppress feeding, decrease body weight and enhance metabolic rate.11–15 Such agents may have clinical potential for managing obesity.

The clinical relevance of these findings is further suggested by evidence that use of prescription antihistamines (H1 blockers), or of antipsychotic drugs that also inhibit H1, is associated with an increased risk for obesity.8 16 Of related interest is a recent Chinese cross-sectional epidemiology correlating dietary histidine inversely with BMI, waist circumference and various markers of metabolic syndrome, in both sexes; this finding remained valid whether daily histidine intake was expressed in absolute terms, or after adjustment for protein and other dietary values.17 In a cross-sectional study enrolling female Japanese students, daily histidine intake, as well as the ratio to histidine to total dietary protein, correlated inversely with daily calorie intake after adjustment for other dietary factors;18 this finding evidently is consistent with the possibility that increased brain histidine uptake can aid appetite control in humans, as it does in rodents. Moreover, a cross-sectional epidemiological study has found that 24 hours urinary excretion of histidine correlates inversely with BMI—likewise pointing to a possible role for histidine in control of energy balance.19

To cite: DiNicolantonio JJ, McCarty MF, OKeefe JH. Role of dietary histidine in the prevention of obesity and metabolic syndrome. Open Heart 2018;5:e000676. doi:10.1136/openhrt-2017-000676
**BRAIN HISTAMINE REGULATES GLUCONEOGENESIS**

The amplification of brain histamine activity achievable with supplemental histidine, in addition to controlling appetite, also provokes a brain signal to the liver that decreases the expression of gluconeogenic enzymes—most notably glucose-6-phosphatase—and thereby reduces hepatic glucose output. A neural signal to Kupffer cells boosts their secretion of IL-6; this acts on hepatocytes to induce activating tyrosine phosphorylation of Stat3, which in turn transcriptionally represses gluconeogenic enzyme expression. Intracerebral insulin works in a complementary and analogous manner to restrain hepatic glucose output. These considerations suggest that supplemental histidine could aid glycaemic control in diabetics by downregulating hepatic glucose output—in addition to favourable effects on peripheral insulin sensitivity reflecting histidine's antiobesity/anti-inflammatory actions. It is notable that, in the clinical study evaluating supplemental histidine in women with metabolic syndrome, fasting glucose fell from 5.9 mM at baseline to 5.1 mM after supplementation. And in mice rendered diabetic by streptozotocin administration (a model of type 1 diabetes), plasma glucose averaged 14.3 mM in those who had received histidine in water at 1 g/L for 4 weeks, as opposed to 20.6 mM in those receiving regular water. (Plasma glucose in healthy control mice was 6.3 mM.) A reduction in hepatic glucose output seems likely to be largely responsible for this effect.

**ANTI-INFLAMMATORY EFFECTS**

Supplemental histidine also appears to have anti-inflammatory effects on tissues that are not mediated centrally and independent of its impact on weight control, as suggested by rodent and cell-culture studies. Histidine, as well as its derivative carnosine, can exert antioxidant effects that reflect its ability to scavenge free radicals, quench singlet oxygen and chelate free transition metals. However, it should be noted that histidine availability is not rate limiting for carnosine synthesis. Recent prospective epidemiology has found that higher serum histidine levels predict lower risk for coronary disease in the subsequent years. The impact of dietary histidine on progression of atherosclerosis in rodents has not yet been studied.

**INTERACTION WITH BRANCHED-CHAIN AMINO ACIDS (BCAAS)**

Transport of histidine into the brain may depend not only on plasma histidine level but also on neutral amino acids—including the branched-chain amino acids (BCAAs)—that can compete for access to the neutral amino acid transporter that mediates their transport through the blood–brain barrier. Hence, the rate of brain histidine uptake via this transporter should be proportionate to the plasma ratio of histidine to the sum of other neutral amino acids; this sum is determined primarily by BCAA levels. This observation may be pertinent to cross-sectional studies concluding that plasma levels of BCAAs are elevated in those with type 2 diabetes, metabolic syndrome and/or obesity. Moreover, several prospective studies have found that plasma levels of BCAAs likewise correlated positively with type 2 diabetes risk. Whereas elevated BCAAs might plausibly be an effect of metabolic syndrome, it is also plausible that such elevations could promote weight gain and impair glycaemic control by impeding histidine’s transport into the brain. Indeed, a recent Mendelian randomisation analysis concludes that elevated plasma levels of BCAA are likely to be true mediators of increased risk for type 2 diabetes. This phenomenon would be analogous to the well-known ability of high plasma levels of neutral amino acids to impede brain serotonin production from tryptophan.

With respect to dietary intakes of BCAAs, a recent analysis of three large prospective cohort studies has concluded that calorie-adjusted intakes of BCAAs correlate positively with risk for onset of type 2 diabetes. Although this correlation continued to hold after correction for a range of covariates, it was substantially attenuated, though not eliminated, by adjustment for BMI—consistent with the possibility that elevated BCAA intake was interfering with histidine-dependent central mechanisms for regulating appetite and glycaemic control. However, a smaller Japanese prospective study reached the opposite conclusion—that higher dietary intakes of BCAAs predicted lower risk for diabetes. Arguably, the true dietary determinant of risk might be the ratio of histidine to BCAAs or total neutral amino acids; in this case, such a ratio, in the diet or in plasma, might better predict risk than either histidine or BCAAs per se.

**CAUTIONS**

Supplemental histidine may have the potential to increase histamine production by gastric enterochromaffin cells and by mast cells. Indeed, one rat study has found that stomach levels of histamine are increased as histidine intake increases beyond normal dietary levels. Hence, in susceptible individuals, supplemental histidine could conceivably increase risk for peptic ulcers by boosting gastric acid secretion. If this proves to be the case, supplemental histidine might be contraindicated in those prone to such ulcers or should be administered in conjunction with H2 receptor antagonists. The possibility that histidine supplementation could amplify symptoms in those prone to allergies by increasing histamine production in mast cells should also be considered. Moreover, it should be emphasised that there has so far been little clinical experience with histidine supplementation, and further controlled studies are needed to determine whether such supplementation can genuinely benefit human body composition and metabolic syndrome.

**Contributors** All authors contributed to the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests JJD is the author of The Salt Fix and has a website themartix.com. JDK and MFM own nutraceutical companies.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correction notice In the end matter, ‘Provenance and peer review’ statement has been correctly updated as ‘Not commissioned; externally peer reviewed’.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

ORCID iD
James H Okereke http://orcid.org/0000-0002-3376-5822

REFERENCES


8. He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. *CNS Drugs* 2012;26:423–34.


